Plain-English translation of NCT05917028 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing a new procedure called Transcatheter Arterial Micro-Embolization (TAME) using Nexsphere-F, which is designed to reduce knee arthritis pain by blocking abnormal blood vessels in the joint. The procedure is for people over 50 whose knee pain hasn't gotten better despite trying standard treatments like physical therapy, glucosamine supplements, and joint injections. Researchers want to see if this treatment is safe and effective for people with moderate arthritis who still have significant pain.
Many people with knee arthritis continue to have pain even after trying all the usual treatments, and their options become limited. This trial exists to explore whether blocking the abnormal blood vessels that may contribute to pain could be a new option for these patients who need help but may not be ready for or suitable for knee replacement surgery.
You likely qualify if…
You likely don't qualify if…
If you enroll, you will sign detailed consent forms before the procedure and have baseline tests including an MRI scan and pain assessments. On the day of the procedure, doctors will use imaging to look for abnormal blood vessels in your knee, and if found, they will block them using the new Nexsphere-F material through a small catheter (a thin tube inserted into an artery). After the procedure, you'll be monitored and asked to track your pain and knee function over time using standard pain and mobility scales.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
South Korea
Sponsor
Next Biomedical Co., Ltd.
Enrollment target
~20 participants
Started
October 2023
Primary completion
December 2025
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
50 Years and older
Last updated on clinicaltrials.gov in April 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Hyuckmin Kwon
Severance Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.